Data completeness
3/8 — Basic
Ruxolitinib (ruxolitinib) by Incyte is janus kinase inhibitors [moa]. Approved for myelofibrosis, polycythemia vera, graft-versus-host disease.
Drug data last refreshed 2w ago
Mechanism of Action
Janus Kinase Inhibitors
Worked on Ruxolitinib at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.